Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition-Reference-Cited by-同舟云学术

Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition

Published:2017-07-26 Issue:400 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Yang Lu¹²,Zhang Youyou¹,Shan Weiwei¹³,Hu Zhongyi¹,Yuan Jiao¹^ORCID,Pi Jingjiang¹^ORCID,Wang Yueying¹,Fan Lingling¹³,Tang Zhaoqing¹,Li Chunsheng¹⁴^ORCID,Hu Xiaowen¹⁴,Tanyi Janos L.⁴,Fan Yi⁵,Huang Qihong⁶,Montone Kathleen⁷,Dang Chi V.⁸^ORCID,Zhang Lin¹⁴⁸^ORCID

Affiliation:

1. Center for Research on Reproduction and Women’s Health, University of Pennsylvania, Philadelphia, PA 19104, USA.

2. Department of Obstetrics and Gynecology, West China Medical School, Sichuan University, Chengdu 610041, China.

3. Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China.

4. Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA.

5. Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.

6. Wistar Institute, Philadelphia, PA 19104, USA.

7. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

8. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.

Abstract

PARP inhibitors can be combined with BET inhibitors to treat cancers with de novo or acquired resistance to PARP inhibition.

Funder

National Institutes of Health

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference61 articles.

1. Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors

2. Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development

3. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

4. Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function

5. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

Cited by 201 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes;Expert Review of Anticancer Therapy;2024-09-03

2. Circulating tumor cells: from new biological insights to clinical practice;Signal Transduction and Targeted Therapy;2024-09-02

3. Therapeutic targeting of PARP with immunotherapy in acute myeloid leukemia;Frontiers in Pharmacology;2024-08-08

4. Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer;Frontiers in Oncology;2024-08-02

5. Effects of PARP Inhibitors on Subsequent Platinum-Based Chemotherapy in Patients with Recurrent Ovarian Cancer;Cancers;2024-07-25